-
proteins (NMRC)". Human kinases and epigenetic proteins are important therapeutic targets. Recent development of selective and potent inhibitors of proteins has yielded remarkable results in disease
-
– Development of Lysine-Targeting, Cell-Active Covalent Inhibitors (CIs) with High Potency and Selectivity (MOE T2)". Human kinases and epigenetic proteins are important therapeutic targets. Recent development
-
proteins (NMRC)". Human kinases and epigenetic proteins are important therapeutic targets. Recent development of selective and potent inhibitors of proteins has yielded remarkable results in disease
-
high quality publications to disseminate the research outcomes. Modelling potential compounds and exploring their spectral analysis. Develop quantitative structure activity relationship (QSAR) models